Research programme: amyloid precursor protein secretase inhibitors - Cotinga Pharmaceuticals

Drug Profile

Research programme: amyloid precursor protein secretase inhibitors - Cotinga Pharmaceuticals

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Critical Outcome Technologies
  • Developer Cotinga Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Canada (PO)
  • 27 Jul 2009 The programme is available for co-development(
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top